ZEB2 and central nervous system cancer: The same effect was observed with miR-378, which inhibited EMT by targeting cis-aconitate decarboxylase (IRG1) in gliomas [67], miR-139-5p by targeting the notch1 oncogene in gliomas [68], miR-181a by targeting ZBTB33 expression in glioma cells [69], miR-623 by targeting TRIM-44 [70], miR-940 by targeting ZEB2 [71], and miR-7, which targeted T-Box 2 in glioblastoma [72].